Johnson & Johnson (NYSE: JNJ) reported its first-quarter results before market open. The company disclosed that its earnings per share slightly exceeded analyst expectations, while revenue surpassed estimates and showed an increase compared to the previous year.
In the first quarter, the company generated adjusted earnings of $2.70 per share, surpassing the consensus estimate of $2.67. This figure, however, represents a decrease from the $2.77 per share recorded in the same period last year.
Revenue for the quarter reached $24.06 billion, exceeding the anticipated $23.63 billion and reflecting an increase from the $21.89 billion reported a year ago.
Innovative Medicine worldwide operational sales grew by 7.4 percent, with net acquisitions and divestitures contributing positively by 1.8 percent, mainly due to CAPLYTA. MedTech worldwide operational sales increased by 4.6 percent, with divestitures slightly impacting growth by 0.1 percent.
JNJ recorded operational growth of 6.4 percent and adjusted operational growth of 5.3 percent in the first quarter of 2026.
Joaquin Duato, Chairman and Chief Executive Officer, Johnson & Johnson, commented, “Johnson & Johnson had a strong start to 2026 and is delivering on its promise for a year of accelerated growth and impact.”
For the full year 2026, Johnson & Johnson revised its earnings outlook to a range of $11.45 to $11.65 per share, up from the previous guidance of $11.43 to $11.63.
The revenue outlook was also adjusted, now expected to be between $100.30 billion and $101.30 billion, compared to the earlier range of $99.50 billion to $100.50 billion.
 reported its first-quarter earnings per share slightly exceeded analyst expectations,){kind=link}